homepage-top-section

INO-4800 features a particularly designed deoxyribonucleic acid (DNA) plasmid. To be injected intradermally with subsequent electroporation, INO-4800 carries the DNA plasmid directly into body cells. Inovio’s partner, Advaccine

BRII-196 and BRII-198 are non-competing monoclonal antibodies obtained from convalesced Covid-19 patients. These antibodies neutralise SARS-CoV-2. The trial is funded by the NIH unit National Institute of Allergy

The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate. NVX-CoV2373 is

Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development. Under terms of

Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.

The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ investigational Covid-19 antibody cocktail REGEN-COV. Designed to block SARS-CoV-2 infectivity, REGEN-COV

The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Eli Lilly and Company and Incyte’s baricitinib to treat Covid-19 patients with or

GlaxoSmithKline (GSK) and Vir Biotechnology have announced a joint procurement agreement with the European Commission for the supply of up to 220,000 doses of sotrovimab to treat Covid-19

Biotechnology company Amgen has agreed to acquire Teneobio, a privately held clinical stage biotechnology firm, in a deal valued at about $900m. Teneobio is developing a new class